MoonLake Immunotherapeutics Faces Class Action Lawsuit Over Securities Fraud Allegations

Reuters

2025/12/12

<a href="https://laohu8.com/S/MLTX">MoonLake Immunotherapeutics</a> Faces Class Action Lawsuit Over Securities Fraud Allegations

A class action lawsuit has been filed against Moonlake Immunotherapeutics, alleging securities fraud that affected investors between March 10, 2024, and September 29, 2025. The complaint claims that the company made false statements or concealed material information regarding its sole drug candidate, SLK, specifically its similarities to BIMZELX in targeting inflammatory cytokines IL-17A and IL-17F. It is alleged that the company misrepresented the purported clinical advantages of SLK's Nanobody structure, including claims that it would offer superior clinical benefits and increased tissue penetration compared to traditional monoclonal antibodies. Based on these allegations, the lawsuit asserts that Moonlake Immunotherapeutics lacked a reasonable basis for its positive statements about SLK's superiority. Investors who experienced losses during the specified period are represented in this case.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moonlake Immunotherapeutics published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1116996) on December 12, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2590179506"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2590179506\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2590179506?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-12 20:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590179506","market":"fut","top_or_hot":-1,"title":"MoonLake Immunotherapeutics Faces Class Action Lawsuit Over Securities Fraud Allegations","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MLTX\">MoonLake Immunotherapeutics</a> Faces Class Action Lawsuit Over Securities Fraud Allegations\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        A class action lawsuit has been filed against Moonlake Immunotherapeutics, alleging securities fraud that affected investors between March 10, 2024, and September 29, 2025. The complaint claims that the company made false statements or concealed material information regarding its sole drug candidate, SLK, specifically its similarities to BIMZELX in targeting inflammatory cytokines IL-17A and IL-17F. It is alleged that the company misrepresented the purported clinical advantages of SLK's Nanobody structure, including claims that it would offer superior clinical benefits and increased tissue penetration compared to traditional monoclonal antibodies. Based on these allegations, the lawsuit asserts that Moonlake Immunotherapeutics lacked a reasonable basis for its positive statements about SLK's superiority. Investors who experienced losses during the specified period are represented in this case.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moonlake Immunotherapeutics published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1116996) on December 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MoonLake Immunotherapeutics Faces Class Action Lawsuit Over Securities Fraud Allegations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMoonLake Immunotherapeutics Faces Class Action Lawsuit Over Securities Fraud Allegations\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-12-12 20:42</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MLTX\">MoonLake Immunotherapeutics</a> Faces Class Action Lawsuit Over Securities Fraud Allegations\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        A class action lawsuit has been filed against Moonlake Immunotherapeutics, alleging securities fraud that affected investors between March 10, 2024, and September 29, 2025. The complaint claims that the company made false statements or concealed material information regarding its sole drug candidate, SLK, specifically its similarities to BIMZELX in targeting inflammatory cytokines IL-17A and IL-17F. It is alleged that the company misrepresented the purported clinical advantages of SLK's Nanobody structure, including claims that it would offer superior clinical benefits and increased tissue penetration compared to traditional monoclonal antibodies. Based on these allegations, the lawsuit asserts that Moonlake Immunotherapeutics lacked a reasonable basis for its positive statements about SLK's superiority. Investors who experienced losses during the specified period are represented in this case.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moonlake Immunotherapeutics published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1116996) on December 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDL3PzFVR:1","article_id":"2590179506","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590179506","pubTimestamp":1765543341,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"A class action lawsuit has been filed against Moonlake Immunotherapeutics, alleging securities fraud that affected investors between March 10, 2024, and September 29, 2025. The complaint claims that the company made false statements or concealed material information regarding its sole drug candidate, SLK, specifically its similarities to BIMZELX in targeting inflammatory cytokines IL-17A and IL-17F. It is alleged that the company misrepresented the purported clinical advantages of SLK's Nanobody structure, including claims that it would offer superior clinical benefits and increased tissue penetration compared to traditional monoclonal antibodies. Based on these allegations, the lawsuit asserts that Moonlake Immunotherapeutics lacked a reasonable basis for its positive statements about SLK's superiority. Investors who experienced losses during the specified period are represented in this case.Disclaimer: This news brief was created by Public Technologies  using generative artificial in","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","MLTX":"MoonLake Immunotherapeutics"},"translate_title":"MoonLake Immunotherapeutics因证券欺诈指控面临集体诉讼","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MLTX":0.9},"content_text":"MoonLake Immunotherapeutics Faces Class Action Lawsuit Over Securities Fraud Allegations\n    \n\n        A class action lawsuit has been filed against Moonlake Immunotherapeutics, alleging securities fraud that affected investors between March 10, 2024, and September 29, 2025. The complaint claims that the company made false statements or concealed material information regarding its sole drug candidate, SLK, specifically its similarities to BIMZELX in targeting inflammatory cytokines IL-17A and IL-17F. It is alleged that the company misrepresented the purported clinical advantages of SLK's Nanobody structure, including claims that it would offer superior clinical benefits and increased tissue penetration compared to traditional monoclonal antibodies. Based on these allegations, the lawsuit asserts that Moonlake Immunotherapeutics lacked a reasonable basis for its positive statements about SLK's superiority. Investors who experienced losses during the specified period are represented in this case.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moonlake Immunotherapeutics published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1116996) on December 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory,event","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}